163 related articles for article (PubMed ID: 10389621)
1. Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis.
Helpap B; Köllermann J
Virchows Arch; 1999 May; 434(5):385-91. PubMed ID: 10389621
[TBL] [Abstract][Full Text] [Related]
2. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma.
Aprikian AG; Cordon-Cardo C; Fair WR; Reuter VE
Cancer; 1993 Jun; 71(12):3952-65. PubMed ID: 7685237
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study.
Turbat-Herrera EA; Herrera GA; Gore I; Lott RL; Grizzle WE; Bonnin JM
Arch Pathol Lab Med; 1988 Nov; 112(11):1100-5. PubMed ID: 2460064
[TBL] [Abstract][Full Text] [Related]
4. [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases].
Sakuma T; Yoshida T; Ohashi H; Nishimura K; Kawano K
Hinyokika Kiyo; 2007 Jul; 53(7):489-92. PubMed ID: 17702184
[TBL] [Abstract][Full Text] [Related]
5. Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity.
Roudier MP; True LD; Vessella RL; Higano CS
J Clin Pathol; 2004 Mar; 57(3):321-3. PubMed ID: 14990610
[TBL] [Abstract][Full Text] [Related]
6. Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?
Prendeville S; Al-Bozom I; Compérat E; Sweet J; Evans AJ; Ben-Gashir M; Mete O; van der Kwast TH; Downes MR
Histopathology; 2017 Dec; 71(6):926-933. PubMed ID: 28756619
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine stains and proliferative indices of prostatic adenocarcinomas in transurethral resection samples.
Speights VO; Cohen MK; Riggs MW; Coffield KS; Keegan G; Arber DA
Br J Urol; 1997 Aug; 80(2):281-6. PubMed ID: 9284203
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine differentiation in prostate cancer.
Cerović SJ; Brajusković GR; Vukotić Maletić VD; Mićić SR
Vojnosanit Pregl; 2004; 61(5):513-8. PubMed ID: 15551804
[TBL] [Abstract][Full Text] [Related]
10. A more objective staging of advanced prostate cancer--routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values.
Tarle M; Frković-Grazio S; Kraljić I; Kovacić K
Prostate; 1994; 24(3):143-8. PubMed ID: 7509485
[TBL] [Abstract][Full Text] [Related]
11. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical study of neuroendocrine differentiation in primary glandular lesions and tumors of the urinary bladder.
Bollito ER; Pacchioni D; Lopez-Beltran A; Volante M; Terrone C; Casetta G; Mari M; DePompa R; Cappia S; Papotti M
Anal Quant Cytol Histol; 2005 Aug; 27(4):218-24. PubMed ID: 16220833
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL
Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329
[TBL] [Abstract][Full Text] [Related]
14. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
17. Small cell undifferentiated carcinoma of the submandibular gland with neuroendocrine features.
de Vicente Rodríguez JC; Fresno Forcelledo MF; Junquera Gutiérrez LM; Hernández Vallejo G; López Arranz JS
Ann Otol Rhinol Laryngol; 2004 Jan; 113(1):55-9. PubMed ID: 14763575
[TBL] [Abstract][Full Text] [Related]
18. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.
Epstein JI; Amin MB; Beltran H; Lotan TL; Mosquera JM; Reuter VE; Robinson BD; Troncoso P; Rubin MA
Am J Surg Pathol; 2014 Jun; 38(6):756-67. PubMed ID: 24705311
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutical perspectives.
Helpap B; Köllermann J; Oehler U
Urol Int; 1999; 62(3):133-8. PubMed ID: 10529661
[TBL] [Abstract][Full Text] [Related]
20. Paneth cell-like change in prostatic adenocarcinoma represents neuroendocrine differentiation: report of 30 cases.
Adlakha H; Bostwick DG
Hum Pathol; 1994 Feb; 25(2):135-9. PubMed ID: 7509774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
